Axsome Therapeutics (AXSM) Stock Analysis & Winston Score

Axsome Therapeutics is a pharmaceutical company that develops and sells medicines for brain and nervous system disorders. Its main products include Auvelity, a fast-acting pill for major depressive disorder, and Sunosi, a treatment for excessive daytime sleepiness. The company sells these drugs primarily to patients in the United States through prescriptions written by psychiatrists and other doctors. Axsome makes money by selling its approved medications directly to pharmacies and specialty distributors, earning revenue each time a prescription is filled. The company operates almost entirely in the US market and is relatively small, with an $11.5 billion market cap. Its high gross margin of 93% reflects the typical economics of branded pharmaceuticals, but it is still spending more than it earns, posting a negative operating margin as it invests heavily in sales and marketing to grow its newer drugs. The key growth driver is continued adoption of Auvelity in a large and underserved depression market, while the main risk is competition from generic antidepressants and potential pricing pressure.